SPR Therapeutics has announced that Marc Huntoon, director of pain management at the Neuroscience, Orthopaedic and Wellness Center, VCU Medical Center, was the first to use the recently FDA-cleared SPRINT endura single-lead peripheral nerve stimulation (PNS) system, for the treatment of complex regional pain syndrome (CRPS).
CRPS is a debilitating, chronic pain condition affecting the limbs that can be induced by surgery, trauma or injury. While CRPS can be very difficult to treat, earlier intervention has been shown to improve outcomes, and PNS can be an effective option. Historically, PNS involved an invasive neurosurgical procedure, and as a result it was not often considered as an early treatment option. The SPRINT system is a minimally invasive PNS option that is conducive to use early in the treatment continuum.
“I have been treating complex regional pain syndrome for nearly three decades. In my experience, patients suffering from chronic pain benefit from early intervention with peripheral nerve stimulation. Now that there is a less invasive percutaneous option, PNS can more easily be deployed sooner in the care continuum,” said Huntoon of VCU Medical Center. “In my experience, this new method of peripheral nerve stimulation is generally safe, effective and minimally invasive.” In addition to treating CRPS it has also been helpful in treating other pain conditions such as back pain, shoulder pain, post-amputation pain, and pain following surgery, such as total knee replacement.
“We are pleased to see accelerated adoption of the latest version of our SPRINT peripheral nerve stimulation system following its recent FDA clearance. It is gratifying to see the SPRINT system being prescribed earlier in the disease process for a broad range of pain disorders—including CRP—due to our technology’s minimally invasive and patient-friendly features,” said Maria Bennett, founder, president and CEO of SPR Therapeutics.
